Middle East Healthcare Co.’s (Saudi German Health) earnings rose to SAR 301.9 million for 2025, compared with SAR 282 million a year earlier.
| Item | 2024 | 2025 | Change |
|---|---|---|---|
| Revenues | 2,882.82 | 3,102.63 | 7.6 % |
| Gross Income | 1,113.90 | 1,160.04 | 4.1 % |
| Operating Income | 440.93 | 387.30 | (12.2 %) |
| Net Income | 282.00 | 301.88 | 7.0 % |
| Average Shares | 92.04 | 92.04 | - |
| Earnings Per Share before unusual items (Riyals) | 2.36 | 2.04 | (13.5 %) |
| EPS (Riyal) | 3.06 | 3.28 | 7.0 % |
The annual profit rise was driven by improved revenues, resulting from the growth in the total number of inpatient and outpatient visits, coupled with expansion of the group’s operational bed capacity across select facilities.
The company also cited a one-off contract awarded by the Ministry of Health to operate the Mina II Emergency Hospital during the 2025 Hajj season.
Besides, a decline in net financing expenses due to improved leverage and lower interest rates, and recognition of a one-off capital gain of SAR 114 million from the sale of undeveloped land in Riyadh.
As for Q4 2025, the company reported a net profit of SAR 37.79 million, down 66% from SAR 111.29 million in the fourth quarter of 2024.
Sequentially, the bottom line fell by 6.2% from SAR 40.29 million in Q3 2025.
| Item | Q4 2024 | Q4 2025 | Change |
|---|---|---|---|
| Revenues | 748.88 | 808.79 | 8.0 % |
| Gross Income | 282.07 | 284.40 | 0.8 % |
| Operating Income | 101.69 | 86.97 | (14.5 %) |
| Net Income | 111.29 | 37.79 | (66.0 %) |
| Average Shares | 92.04 | 92.04 | - |
| Earnings Per Share before unusual items (Riyal) | 0.72 | 0.41 | (42.6 %) |
| EPS (Riyal) | 1.21 | 0.41 | (66.0 %) |
| Item | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Revenues | 768.97 | 808.79 | 5.2 % |
| Gross Income | 283.95 | 284.40 | 0.2 % |
| Operating Income | 87.44 | 86.97 | (0.5 %) |
| Net Income | 40.29 | 37.79 | (6.2 %) |
| Average Shares | 92.04 | 92.04 | - |
| Earnings Per Share before unusual items (Riyal) | 0.44 | 0.41 | (6.2 %) |
| EPS (Riyal) | 0.44 | 0.41 | (6.2 %) |
Shareholders’ equity, after minority interest, stood at SAR 1.87 billion by the end of 2025, up from SAR 1.62 billion a year earlier.
| Company | Estimated | Actual | Change |
|---|---|---|---|
| SAUDI GERMAN HEALTH | 57.43 | 37.79 | |
| MARAFIQ | 54.00 | 51.22 | |
| JAMJOOM PHARMA | 72.76 | 68.07 | |
| SSP | 25.90 | 44.66 | |
| SHAKER | 16.30 | 16.83 | |
| LEEJAM SPORTS | 88.58 | 79.00 | |
| CARE | 86.37 | 70.96 | |
| STC | 3,507.08 | 3,248.66 | |
| QACCO | 53.90 | 68.86 | |
| ETIHAD ETISALAT | 887.42 | 953.39 |
| Company | Estimated | Actual | Change |
|---|---|---|---|
| SAUDI GERMAN HEALTH | 57.43 | 37.79 | |
| MARAFIQ | 54.00 | 51.22 | |
| JAMJOOM PHARMA | 72.76 | 68.07 | |
| SSP | 25.90 | 44.66 | |
| SHAKER | 16.30 | 16.83 | |
| LEEJAM SPORTS | 88.58 | 88.60 | |
| CARE | 86.37 | 70.96 | |
| STC | 3,507.08 | 3,118.65 | |
| QACCO | 53.90 | 68.86 | |
| ETIHAD ETISALAT | 887.42 | 953.39 |
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: